HighTower Advisors LLC Reduces Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

HighTower Advisors LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 30,302 shares of the biopharmaceutical company’s stock after selling 2,723 shares during the quarter. HighTower Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $21,585,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. State Street Corp grew its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after purchasing an additional 61,277 shares during the last quarter. Amundi grew its holdings in shares of Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company’s stock worth $495,639,000 after buying an additional 22,538 shares during the last quarter. Swiss National Bank grew its holdings in shares of Regeneron Pharmaceuticals by 0.6% during the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock worth $338,079,000 after buying an additional 2,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 0.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock worth $215,562,000 after buying an additional 1,108 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 2.0 %

Shares of Regeneron Pharmaceuticals stock opened at $666.87 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a market capitalization of $72.91 billion, a P/E ratio of 17.42, a P/E/G ratio of 2.34 and a beta of 0.27. The business has a 50 day moving average price of $694.91 and a 200 day moving average price of $833.75.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $11.86 EPS. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.53%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Robert W. Baird lowered their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. Sanford C. Bernstein lowered their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. Finally, Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.